Skip to main content
. 2020 Jun 2;20:491. doi: 10.1186/s12885-020-06998-9

Table 2.

Anamnestic data of 1009 patients with “Triple Negative” breast cancer based on histologic subtypes. Sardinia, Italy 1994–2015

IBC-NST
(n = 744)
n (%)
Lobular
(n = 62)
n (%)
Apocrine
(n = 43)
n (%)
Adenoid cystic
(n = 6)
n (%)
Metaplastic
(n = 46)
n (%)
Medullary
(n = 39)
n (%)
Other
(n = 27)
n (%)
p value*
Age
  < 35 34 (4.6) 0 (0.0) 2 (4.7) 1 (16.7) 3 (6.5) 6 (15.4) 1 (3.7) < 0.001
 35–49 214 (28.8) 10 (16.1) 1 (2.3) 1 (16.7) 8 (17.4) 12 (30.8) 8 (29.6)
 50–69 354 (47.6) 36 (58.1) 22 (51.2) 3 (50.0) 26 (56.5) 18 (46.2) 16 (59.3)
 70+ 141 (19.0) 16 (25.8) 18 (41.9) 1 (16.7) 9 (19.6) 3 (7.7) 2 (7.4)
 Missing 1
Age at menarche
  < 13 208 (45.9) 10 (31.3) 11 (37.9) 0 (0.0) 9 (27.3) 7 (43.8) 4 (19.0) 0.036
  ≥ 13 245 (54.1) 22 (68.8) 18 (62.1) 2 (100.0) 24 (72.7) 9 (56.3) 17 (81.0)
 Missing 291 30 14 4
Age at menopause
  < 45 34 (11.8) 3 (12.0) 2 (7.7) 1 (50.0) 1 (4.3) 2 (18.2) 1 (7.7) 0.519
  ≥ 45 253 (88.2) 22 (88.0) 24 (92.3) 1 (50.0) 22 (95.7) 9 (81.8) 12 (92.3)
 Missing 457 37 17 3 23 27 14
Menopausal status
 yes 210 (47.6) 18 (66.7) 17 (63.0) 1 (33.3) 20 (60.6) 10 (52.6) 12 (54.5) 0.124
 post surgical 39 (8.8) 3 (11.1) 4 (14.8) 1 (33.3) 2 (6.1) 2 (10.5) 1 (4.5)
 post treatment 2 (0.5) 0 (0.0) 1 (3.7) 0 (0.0) 0 (0.0) 1 (5.3) 0 (0.0)
 no 190 (43.1) 6 (22.2) 5 (18.5) 1 (33.3) 11 (33.3) 6 (31.6) 9 (40.9)
 Missing 303 35 16 3 13 20 5
Nulliparity
 yes 80 (16.4) 1 (3.1) 7 (25.0) 0 (0.0) 7 (19.4) 4 (25.0) 4 (20.0) 0.280
 no 409 (83.6) 31 (96.9) 21 (75.0) 3 (100.0) 29 (80.6) 12 (75.0) 16 (80.0)
 Missing 255 30 15 3 10 22 7
Family history of breast cancer
 yes 166 (33.8) 9 (23.7) 11 (36.7) 3 (100.0) 13 (37.1) 9 (45.0) 5 (21.7) 0.104
 no 325 (66.2) 29 (76.3) 19 (63.3) 0 (0.0) 22 (62.9) 11 (55.0) 18 (78.3)
 Missing 253 24 13 3 11 19 4
Family history of other than breast cancer
 yes 137 (29.1) 14 (38.9) 6 (20.7) 0 (0.0) 8 (25.0) 6 (35.3) 10 (45.5) 0.309
 no 333 (70.9) 22 (61.1) 23 (79.3) 3 (100.0) 24 (75.0) 11 (64.7) 12 (54.5)
 Missing 274 26 14 3 14 20 5
Other concomitant primary cancer
 yes 11 (4.5) 1 (5.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0.870
 no 231 (95.5) 19 (95.0) 12 (100.0) 2 (100.0) 19 (100.0) 8 (100.0) 11 (100.0)
 Missing 502 42 31 4 27 31 16
Other previous primary cancer
 yes 19 (7.3) 1 (5.0) 3 (20.0) 0 (0.0) 0 (0.0) 1 (11.1) 0 (0.0) 0.361
 no 242 (92.7) 19 (95.0) 12 (80.0) 2 (100.0) 19 (100.0) 8 (88.9) 11 (100.0)
 Missing 483 42 28 4 27 30 16
BMI
  < 18 underweight 14 (3.0) 0 (0.0) 0 (0.0) 1 (33.3) 0 (0.0) 0 (0.0) 2 (10.0) 0.183
 18–24.9 normal range 235 (50.8) 15 (46.9) 11 (42.3) 1 (33.3) 18 (54.5) 8 (47.1) 8 (40.0)
 25–30 overweight 135 (29.2) 11 (34.4) 7 (26.9) 1 (33.3) 11 (33.3) 7 (41.2) 7 (35.0)
  > 30 0bese 79 (17.1) 6 (18.8) 8 (30.8) 0 (0.0) 4 (12.1) 2 (11.8) 3 (15.0)
 Missing 281 30 17 3 13 22 7
Drinking
 yes 21 (4.9) 1 (3.1) 0 (0.0) 1 (33.3) 0 (0.0) 3 (21.4) 1 (4.8) 0.015
 no 407 (95.1) 31 (96.9) 22 (100.0) 2 (66.7) 32 (100.0) 11 (78.6) 20 (95.2)
 Missing 316 30 21 3 14 24 6
Smoking
 yes 92 (20.2) 5 (14.7) 4 (16.0) 1 (3.3) 7 (21.2) 3 (18.8) 3 (13.6) 0.942
 no 364 (79.8) 29 (85.3) 21 (84.0) 2 (66.7) 26 (78.8) 13 (81.3) 19 (86.4)
 Missing 288 28 18 3 13 22 5

*The p-value are bold where they are less than or equal to the significance level of 0.05